December 16, 2024 — The closing days of 2024 give us a moment to reflect on the stories that defined this year in obesity and health. It’s been a big year, with no shortage of news on this subject. But the major themes stand out very clearly. Health Outcomes Beyond Weight Loss This was the year that objective evidence […]
November 26, 2024 — For the second time this year, we have a meta-analysis of RCTs with GLP-1 medicines that affirms cardiorenal benefits in outcome studies. This latest study appears in Lancet Diabetes and Endocrinology. Lead author Sunil Badve described the importance of his analysis: “This is the first study to show a clear benefit of GLP-1 receptor agonists […]
November 17, 2024 — By 38%, Tirzepatide cuts the risk of bad outcomes in persons with obesity and an increasingly common form of heart failure that obesity causes. The diagnosis is heart failure with preserved ejection fraction or HFpEF. The measure of bad outcomes it prevents was a composite worsening heart failure or death from cardiovascular disease. Worsening heart […]
June 22, 2024 — We like to celebrate firsts. And yesterday, we got one to celebrate in the first ever drug treatment shown to be effective for sleep apnea – the obesity medicine called tirzepatide. In presenting this new research at the American Diabetes Association Scientific Sessions yesterday, Atul Malhotra reminded us, “sleep is an important part of cardiometabolic […]
June 9, 2024 — At the EASL Congress 2024 in Milan, we witnessed quite a splash of new data on both survodutide and tirzepatide for MASH. Friday and Saturday gave us two headline presentations at the meeting and two publications in the New England Journal of Medicine. Lilly pronounced itself “very pleased” with the results of their SYNERGY-NASH study […]
June 8, 2024 — Puberty is coming earlier for girls today, obesity in children is rising, and endocrine disruption seems to be playing a role in both of these phenomena. What’s more, exposure to endocrine disruptors follows a pattern of health disparities. This means that these environmental hazards may have the greatest effects on populations that already suffer disadvantages […]
March 22, 2024 — A profound shift in the understanding of medicines that help with excessive or abnormal fat is underway. A few years ago, everybody thought of these in only one frame of reference – weight loss drugs. But that is changing now. Discourse about them is moving from weight loss to obesity treatment and even further, to […]
March 9, 2024 — It’s official. FDA now says that semaglutide, in doses used to treat obesity, can prevent heart attacks, strokes, and deaths in persons with cardiovascular disease and overweight or obesity. This is nothing short of the dawn of a new era in obesity treatment. FDA Division Director John Sharretts said it clearly: “This patient population has […]
October 13, 2023 — The handwriting is on the wall. Insurers can’t avoid covering obesity drugs forever, said a recent analysis from Bloomberg and they were right. What prompted that conclusion is the cascade of health outcome studies that make it unmistakeable. Treating obesity and and related metabolic diseases with advanced medicines like semaglutide has a dramatic effect on […]
February 12, 2022 — To each his own – because truly, one size will never fit all. We can find no better illustration for this than the idea that perfectly healthy people might want to wear a continuous glucose monitors. And yet we have a crop of new tech startups that want to put these glucose monitors on all […]
